Evidence map›Paper›PMID 34101765›Full record

ArticlePloS one2021

A new method for the study of biophysical and morphological parameters in 3D cell cultures: Evaluation in LoVo spheroids treated with crizotinib.

Azzurra Sargenti, Francesco Musmeci, Carola Cavallo, Martina Mazzeschi, Simone Bonetti, Simone Pasqua, Francesco Bacchi, Giuseppe Filardo, Daniele Gazzola, Mattia Lauriola and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Azzurra SargentiCell Dynamics iSRL, Bologna, Italy.ORCID 0000-0003-1170-8517
Francesco MusmeciCell Dynamics iSRL, Bologna, Italy.
Carola CavalloRAMSES Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.ORCID 0000-0002-2913-856X
Martina MazzeschiDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.ORCID 0000-0002-4695-9175
Simone BonettiCell Dynamics iSRL, Bologna, Italy.
Simone PasquaCell Dynamics iSRL, Bologna, Italy.
Francesco BacchiCell Dynamics iSRL, Bologna, Italy.
Giuseppe FilardoApplied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Daniele GazzolaCell Dynamics iSRL, Bologna, Italy.
Mattia LauriolaDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Spartaco SantiInstitute of Molecular Genetics "Luigi Luca Cavalli-Sforza", Unit of Bologna, CNR, Bologna, Italy.ORCID 0000-0001-9856-7053
Istituto Ortopedico Rizzoli · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional (3D) culture systems like tumor spheroids represent useful in vitro models for drug screening and more broadly for cancer biology research, but the generation of uniform populations of spheroids remains challenging. The possibility to properly characterize spheroid properties would increase the reliability of these models. To address this issue different analysis were combined: i) a new device and relative analytical method for the accurate, simultaneous, and rapid measurement of mass density, weight, and size of spheroids, ii) confocal imaging, and iii) protein quantification, in a clinically relevant 3D model. The LoVo colon cancer cell line forming spheroids, treated with crizotinib (CZB) an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases, was employed to study and assess the correlation between biophysical and morphological parameters in both live and fixed cells. The new fluidic-based measurements allowed a robust phenotypical characterization of the spheroids structure, offering insights on the spheroids bulk and an accurate measurement of the tumor density. This analysis helps overcome the technical limits of the imaging that hardly penetrates the thickness of 3D structures. Accordingly, we were able to document that CZB treatment has an impact on mass density, which represents a key marker characterizing cancer cell treatment. Spheroid culture is the ultimate technology in drug discovery and the adoption of such precise measurement of the tumor characteristics can represent a key step forward for the accurate testing of treatment's potential in 3D in vitro models.

Indexed as

Antineoplastic AgentsCell Culture TechniquesCell SurvivalColonic NeoplasmsCrizotinibHumansSpheroids, CellularTumor Cells, CulturedAntineoplastic AgentsCrizotinib

Identifiers

PMID34101765
PMCPMC8186796
OpenAlexW3167859905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.